Ignite Creation Date:
2024-05-06 @ 11:17 AM
Last Modification Date:
2024-10-26 @ 12:42 PM
Study NCT ID:
NCT03477461
Status:
COMPLETED
Last Update Posted:
2018-03-26
First Post:
2018-03-13
Brief Title:
Effects of Terlipressin on Management of Potential Organ Donors
Sponsor:
First Affiliated Hospital Sun Yat-Sen University
Organization:
First Affiliated Hospital Sun Yat-Sen University
Study Overview
Official Title:
Effects of Terlipressin on Management of Potential Organ Donorsa Retrospective Study
Status:
COMPLETED
Status Verified Date:
2018-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
During brain death many significant systemic changes take place and among these the most notable is hemodynamic instability
In the pathogenesis of brain death after the hypertensive phase of the catecholamine storm arterial tonus and heart inotropism eventually deteriorate leading to hypotension and hypoperfusion Therefore vasopressor agents are necessary in treatment of brain-dead organ donors The most commonly used and recommended vasoactive drugs for this indication are dopamine norepinephrine and vasopressinThe Transplantation Committee of the American College of Cardiology recommends vasopressin as the primary vasoactive drug for treating hemodynamic instability and diabetes insipidus in brain-death heart donors
Terlipressin TP is a new type of synthetic long-acting vasopressin preparations AVP long-acting derivatives belongs to a kind of precursor drugs itself is inactive the body through the aminopeptidase slow release of a reactive lysine vasopressin On the one handterlipressin can splanchnic vascular smooth muscle contraction reduces splanchnic blood flow eg reduce blood flow to the mesenteric spleen uterus etc to ensure the flow of blood to the important visceraOn the other hand it reduces the concentration of plasma renin increases the perfusion of renal blood flow and improves the glomerular filtration rate thus improving renal functionFrom the pharmacological perspective it is better than arginine vasopressin for the stability of hemodynamics and the perfusion of tissue
Whether or not it has therapeutic effect on the potential brain death donor with unstable hemodynamics is not studied in the literature at home and abroadThis paper discusses the application value of terlipressin in the management of potential brain death and provides clinical evidence for the maintenance of brain death donor
In the pathogenesis of brain death after the hypertensive phase of the catecholamine storm arterial tonus and heart inotropism eventually deteriorate leading to hypotension and hypoperfusion Therefore vasopressor agents are necessary in treatment of brain-dead organ donors The most commonly used and recommended vasoactive drugs for this indication are dopamine norepinephrine and vasopressinThe Transplantation Committee of the American College of Cardiology recommends vasopressin as the primary vasoactive drug for treating hemodynamic instability and diabetes insipidus in brain-death heart donors
Terlipressin TP is a new type of synthetic long-acting vasopressin preparations AVP long-acting derivatives belongs to a kind of precursor drugs itself is inactive the body through the aminopeptidase slow release of a reactive lysine vasopressin On the one handterlipressin can splanchnic vascular smooth muscle contraction reduces splanchnic blood flow eg reduce blood flow to the mesenteric spleen uterus etc to ensure the flow of blood to the important visceraOn the other hand it reduces the concentration of plasma renin increases the perfusion of renal blood flow and improves the glomerular filtration rate thus improving renal functionFrom the pharmacological perspective it is better than arginine vasopressin for the stability of hemodynamics and the perfusion of tissue
Whether or not it has therapeutic effect on the potential brain death donor with unstable hemodynamics is not studied in the literature at home and abroadThis paper discusses the application value of terlipressin in the management of potential brain death and provides clinical evidence for the maintenance of brain death donor
Detailed Description:
Thermodilution cardiac output was measured in triplicate Hemodynamic parameters were calculated according to standard formulasOxygen delivery index IDO2 was calculated as arterial oxygen content multiplied by CI Systemic vascular resistance index SVRI was calculated as the MAP minus right atrial pressure divided by CI and multiplied by 80 Pulmonary vascular resistance index PVRI was calculated as the mean pulmonary artery pressure PAP minus pulmonary artery occlusion pressure divided by CI Left and right ventricular stroke work index L and RVSWI were calculated The following laboratory parameters were collected bilirubin aspartate aminotransferase AST alanine aminotransferase ALTprothrombin time and thrombocytes
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None